DXR

Daxor Corp

Add to Watchlist

Advanced Chart

10.144

+0.144(1.440%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

10.1444

Open

10.000

VWAP

10.07

Vol

2.15K

Mkt Cap

50.34M

Low

10.000

Amount

21.60K

EV/EBITDA(TTM)

81.03

Total Shares

4.84M

50.35M

EV/OCF(TTM)

1.96K

P/S(TTM)

22.27

Daxor Corporation is a diversified, closed-end management investment company. Its focus and operations are as a medical device manufacturing, company. It specializes in blood volume measurement technology focused on blood volume testing innovation. It markets the Blood Volume Analyzer (BVA)-100, the diagnostic blood test cleared by the FDA to provide objective quantification of blood volume status and composition compared to patient-specific norms. Over 65,000 tests have been performed at hospital centers across the United States, enhancing hospital performance metrics in a range of surgical and medical conditions, including reducing mortality and readmissions in heart failure and critical care. Its facility provides on-demand, next day blood volume analysis results. It has several ongoing trials in the areas of heart failure treatment with support from the NIH and is under contract developing analyzers to improve combat casualty care with the United States Department of Defense.

Valuation Metrics

The current forward P/E ratio for Daxor Corp (DXR.O) is 1.93, compared to its 5-year average forward P/E of 18.79. For a more detailed relative valuation and DCF analysis to assess Daxor Corp 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

18.79

Current PE

1.93

Overvalued PE

41.78

Undervalued PE

-4.20

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

15.90

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

43.28

Undervalued EV/EBITDA

-11.48

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Overvalued

5Y Average PS

204.24

Current PS

451.18

Overvalued PS

400.90

Undervalued PS

7.57